Company registers

Investor Relations

Company facts, current operating numbers, and the clinical validation record, in one place.

Investor contact
investors@faexhealth.com

The company at a glance

Faex Health is a preventative healthcare technology company building a longitudinal GI intelligence platform for users, clinicians, and healthcare organizations. The platform combines non-invasive at-home participation, AI-supported analysis, and continuous longitudinal monitoring to produce structured digestive health summaries and pre-screening indicators. Faex MD, the platform's clinician-facing interface, supports professional review and care-team visibility without replacing clinical judgment. The company's mission is to make preventative gastrointestinal health monitoring accessible, scalable, and continuous. Clinical research is underway in Chile, with operations in the United States.

  • Platform reach

    More than 1,000 Source: Faex Health platform analytics

    People registered with the Faex Health platform.

  • Analysis continuation

    70% Among users who completed a first analysis Source: Faex Health platform analytics

Our record so far

  1. May 2024

    Founded at the University of Colorado Boulder.

    Faex began after co-founders Landon Nattrass and Ryan Ninness asked a simple question: why do we monitor almost every aspect of our health, but ignore one of the body's most informative daily signals?

  2. Sep. 2024

    Built the first generation hardware prototype.

    The team initially pursued an automated stool imaging device. After numerous hardware iterations, reliability, manufacturing complexity, and cost made the approach impractical at scale. Rather than forcing the technology, the team pivoted toward smartphone-based computer vision.

  3. Oct. 2024

    AI platform and global research expansion.

    Faex shifted entirely to AI-powered stool analysis using smartphones, rapidly growing its image dataset while working with researchers and clinicians across multiple countries, including projects throughout Africa focused on infectious disease surveillance.

  4. Nov. 2025

    First successful colorectal cancer pre-cancerous polyps detection.

    The platform demonstrated its ability to identify stool characteristics associated with colorectal cancer via pre-cancerous polyps, validating the broader vision that stool images could become an early-warning signal for infectious disease outbreaks and chronic gastrointestinal conditions alike.

  5. 2026

    Clinical validation and healthcare deployment.

    Government-supported clinical studies launched in Chile alongside employer health pilots, expanding Faex toward provider workflows, population health, and national healthcare systems.

Clinical validation evidence

110 registered participants As of July 24, 2026
Registered in the Santiago evaluation
250+ sessions As of July 24, 2026
Longitudinal monitoring sessions recorded
May 2026
Enrollment opened and remains ongoing

Review the full clinical validation record

Leadership and advisors

Leadership

  • Landon Nattrass Co-Founder / CEO
  • Ryan Ninness Co-Founder / CTO
  • Nicholas Soza Head of Operations
  • Jay Yepuri, M.D. Chief Medical Officer
  • Foster Goss, DO, MMSc, FACEP, CMIO Medical / Informatics

Read the company record on About

Advisory board

Advisors serve in an advisory capacity and hold no operating role.

  • Jay Yepuri Chief Medical Officer
  • Foster Goss, DO, MMSc, FACEP, CMIO Medical / Informatics
  • Mark Atkins Military Advisor
  • Bethany Hall-Long Government Advisor

Company news

See the full record in the Press Room

Investor contact

Talk to us directly.

Investor questions reach the team through one inbox, not a form.